Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of LY2216684 in Healthy Subjects Receiving Albuterol or Propanolol

This study has been completed.
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01263197
First received: December 16, 2010
Last updated: April 15, 2011
Last verified: April 2011

December 16, 2010
April 15, 2011
December 2010
March 2011   (final data collection date for primary outcome measure)
Maximum, minimum and average changes in heart rate [ Time Frame: Baseline, Day 1, 3 and 5 ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01263197 on ClinicalTrials.gov Archive Site
Maximum, minimum and average changes in blood pressure [ Time Frame: Baseline, Day 1, 3, and 5 ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
A Study of LY2216684 in Healthy Subjects Receiving Albuterol or Propanolol
Effect of LY2216684 on Heart Rate and Blood Pressure in Healthy Subjects Receiving Oral Doses of Albuterol or Propranolol

The purpose of this study is to determine the effect of LY2216684 on heart rate of healthy people receiving Albuterol and Propranolol. Information about any side effects that may occur will also be collected.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Major Depressive Disorder
  • Drug: LY2216684
    administered orally
  • Drug: albuterol
    administered orally
  • Drug: propranolol
    administered orally
  • Drug: placebo for LY2216684
    administered orally
  • Drug: placebo for albuterol
    administered orally
  • Drug: placebo for propranolol
    administered orally
  • Experimental: LY2216684, albuterol, LY221684+albuterol
    LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in first intervention period, placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a 7 day washout between each intervention period.
    Interventions:
    • Drug: LY2216684
    • Drug: albuterol
    • Drug: placebo for LY2216684
    • Drug: placebo for albuterol
  • Experimental: albuterol, LY2216684+albuterol, LY2216684
    Placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in third intervention period. There is a 7 day washout between each intervention period.
    Interventions:
    • Drug: LY2216684
    • Drug: albuterol
    • Drug: placebo for LY2216684
    • Drug: placebo for albuterol
  • Experimental: LY2216684+albuterol, LY2216684, albuterol
    LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in second intervention period, Placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a 7 day washout between each intervention period.
    Interventions:
    • Drug: LY2216684
    • Drug: albuterol
    • Drug: placebo for LY2216684
    • Drug: placebo for albuterol
  • Experimental: LY2216684, propranolol, LY2216684+propranolol
    LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in first intervention period, placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a 7 day washout between each intervention period.
    Interventions:
    • Drug: LY2216684
    • Drug: propranolol
    • Drug: placebo for LY2216684
    • Drug: placebo for propranolol
  • Experimental: propranolol, LY2216684+propranolol, LY2216684
    Placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in third intervention period. There is a 7 day washout between each intervention period.
    Interventions:
    • Drug: LY2216684
    • Drug: propranolol
    • Drug: placebo for LY2216684
    • Drug: placebo for propranolol
  • Experimental: LY2216684+propranolol, LY2216684, propranolol
    LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in second intervention period, placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a 7 day washout between each intervention period.
    Interventions:
    • Drug: LY2216684
    • Drug: propranolol
    • Drug: placebo for LY2216684
    • Drug: placebo for propranolol
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
48
March 2011
March 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Are overtly healthy, as determined by medical history and physical examination.
  • Male subjects - Agree to use a reliable method of birth control during the study and for 1 month following the last dose of study drug.
  • Female subjects - Are women of child-bearing potential who test negative for pregnancy at the time of enrollment, have used a reliable method of birth control for 6 weeks prior to administration of study drug, and agree to use a reliable method of birth control during the study and for 1 month following the last dose of study drug; or Women not of child-bearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause (at least 1 year without menses or 6 months without menses and a follicle stimulating hormone [FSH] >40 mIU/mL).
  • Have a body weight >50 kg.
  • Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator.
  • Have venous access sufficient to allow blood sampling as per the protocol.
  • Have normal blood pressure and pulse rate (sitting position) as determined by the investigator.
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
  • Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site.

Exclusion Criteria:

  • Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device other than the study drug, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Have known allergies to LY2216684, albuterol (Group 1 only), propranolol (Group 2 only), or related compounds.
  • Are persons who have previously completed or withdrawn from this study or any other study investigating LY2216684 within 6 months prior to screening.
  • Have an abnormality in the 12-lead ECG that, in the opinion of the investigator, increases the risks associated with participating in the study.
  • Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data.
  • Have a history of or current asthma, including exercised induce asthma.
  • Have a history or show evidence of significant active neuropsychiatric disease or have a history of suicide attempt or ideation.
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening.
  • Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies.
  • Show evidence of hepatitis C and/or positive hepatitis C antibody.
  • Show evidence of hepatitis B and/or positive hepatitis B surface antigen.
  • Are women with a positive pregnancy test or women who are lactating.
  • Intend to use over-the-counter or prescription medication (including hormonal contraceptives) within 14 days prior to dosing unless deemed acceptable by the investigator and Sponsor's medical monitor
  • Have donated blood of more than 500 mL within the last month.
  • Have an average weekly alcohol intake that exceeds 14 units per week, or are unwilling to stop alcohol consumption 48 hours prior to check-in in each period and while resident at the CRU (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).
  • Consume 5 or more cups of coffee (or other beverages of comparable caffeine content) per day, on a habitual basis, or any subjects unwilling to adhere to study caffeine restrictions.
  • Have used any tobacco-containing or nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to enrollment.
  • Have consumed grapefruit or grapefruit-containing products 7 days prior to enrollment and during the study.
  • Have a documented or suspected history of glaucoma.
  • Subjects determined to be unsuitable by the investigator for any reason.
Both
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01263197
12598, H9P-EW-LNCI
No
Chief Medical Officer, Eli Lilly
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP